WARRINGTON, Pa., May 5, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announced that data from a preclinical study using Surfaxin(r) (lucinactant) in a well-established preterm lamb model of Respiratory Distress Syndrome (RDS), demonstrated improved lung surfactant distribution as compared with Curosurf(r), the global market-leading animal-derived surfactant available today. The data were presented at the Pediatric Academic Societies Annual Meeting, which is internationally recognized as the largest, most relevant medical congress dedicated to pediatric research.
